Drug intelligence / Profile preview

SP0901 ADC

Development stage: Preclinical
Lead developer: Protheragen
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SP0901 ADC is a discovery-stage antibody-drug conjugate (ADC) developed by Protheragen for the treatment of cancer. The therapeutic is designed to target both Carbonic Anhydrase IX (CAIX) and Epidermal Growth Factor Receptor (EGFR), two antigens frequently overexpressed in various solid tumors. By combining the specificity of monoclonal antibodies with the potency of a cytotoxic payload, SP0901 ADC aims to selectively eliminate tumor cells while sparing healthy tissue. CAIX is particularly relevant in hypoxic tumor environments, while EGFR is a well-known driver of cell proliferation and survival.

Targets

CA9 (Carbonic anhydrase IX)EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on SP0901 ADC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SP0901 ADC.